



## **89bio to Present at the 42nd Annual Raymond James Institutional Investors Conference**

February 24, 2021

SAN FRANCISCO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company's Management will provide a corporate update and participate in one-on-one investor meetings at the Raymond James 42<sup>nd</sup> Annual Institutional Investors Conference on Wednesday, March 3, 2021 at 12:30 PM ET.

The presentation will be available through the [Raymond James conference portal](#) and an archived webcast will also be accessible in the investor section of [89bio's website](#).

### **About 89bio**

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

#### Investor Contact:

Ryan Martins  
Chief Financial Officer  
[investors@89bio.com](mailto:investors@89bio.com)

#### Media Contact:

Peter Duckler  
773-343-3069  
[pduckler@w2ogroup.com](mailto:pduckler@w2ogroup.com)